Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 25

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
 concentrated in the developed technology. We determined that the contingent consideration was within the scope of ASC 480, Distinguishing Liabilities from Equity, because the contingent consideration is payable in cash or shares of our Class A common stock, at our election. The contingent consideration was recorded at fair value as of the acquisition date. Upon closing, we recognized $22.4 million for the fair value of the contingent consideration. Refer to Note 3, Asset Acquisition, in the Notes to condensed consolidated financial statements included in this report, for a description of the fair value measurement of the contingent consideration. 

20

Comparison of the Three and Nine Months Ended September 30, 2025 and 2024

Revenue

Three Months EndedSeptember 30,ChangeNine Months EndedSeptember 30,Change(dollars in thousands)20252024$%20252024$%InstrumentsChromium$4,927 $7,641 $(2,714)(36)%$16,567 $24,283 $(7,716)(32)%Spatial7,072 11,415 (4,343)(38)24,744 44,078 (19,334)(44)Total instruments revenue11,999 19,056 (7,057)(37)41,311 68,361 (27,050)(40)ConsumablesChromium92,519 96,536 (4,017)(4)262,416 274,571 (12,155)(4)Spatial35,373 29,668 5,705 19 103,017 85,330 17,687 21 Total consumables revenue127,892 126,204 1,688 1 365,433 359,901 5,532 2 Services8,128 6,299 1,829 29 24,255 17,292 6,963 40 Products and services revenue148,019 151,559 (3,540)(2)430,999 445,554 (14,555)(3)License and royalty revenue983 95 888 935 45,794 210 45,584 21707 Total revenue$149,002 $151,654 $(2,652)(2)%$476,793 $445,764 $31,029 7 %

Products and services revenue decreased $3.5 million, or 2